Source: Lieyun Network
Recently, Shenzhen Jiyin Biotechnology Co., Ltd. (hereinafter referred to as Jiyin Bio) announced the completion of an angel+ round of financing worth tens of millions of yuan, exclusively invested by Tianchuang Capital. The funds will mainly be used for the optimization and upgrading of the core technology platform and the advancement of in vivo CAR-T pipeline clinical stage work.
Jiyin Bio is a novel immune cell therapy product developer, focusing on the research of new tumor gene and cell therapies. It is committed to the development of iPS-derived universal CAR-NK/T products. Based on proprietary technology platforms such as in vivo CAR-T and iPSC, the company develops universal cell therapy drugs for various indications. By scaling up the production of iPS-derived CAR-NK/T, the company provides off-the-shelf, cost-effective, and insurance-covered novel immune cell therapy products for cancer patients.
Dr. Tu Fan, Investment Director of Tianchuang Capital, stated: Precise in vivo gene delivery is a current research hotspot, and once breakthroughs are achieved, it may represent the next milestone in progress. Viral vectors have been utilized for many years, with benefits far outweighing risks across many indications. The viral vector adopted by JiinGene Bio has demonstrated tremendous potential in preclinical trials, enabling precise in vivo gene delivery to specific cells and holding vast application prospects.